Bayer Aktiengesellschaft (ETR:BAYN)
Germany · Delayed Price · Currency is EUR | Market Cap | 29.95B |
| Revenue (ttm) | 45.87B |
| Net Income (ttm) | -198.00M |
| Shares Out | 982.42M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | 7.96 |
| Dividend | 0.11 (0.36%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 1,852,505 |
| Average Volume | 2,998,318 |
| Open | 30.72 |
| Previous Close | 30.62 |
| Day's Range | 30.38 - 30.79 |
| 52-Week Range | 18.38 - 31.45 |
| Beta | 0.83 |
| RSI | 63.51 |
| Earnings Date | Nov 12, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial StatementsNews
BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study
Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study
Bayer AG (OTC: BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study
Bayer AG (OTC: BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian. • BMY shares are climbing. Find out why her...
European Stocks Rise on Fed's Dovish Signals; Bayer (BAYN) Surges
European Stocks Rise on Fed's Dovish Signals; Bayer (BAYN) Surges
Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer
Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.
Pharma market shake-up: Bayer jumps, Novo Nordisk sinks 10%
Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the disease in a trial. Meanwhile, Germany's Bayer said their stroke-prevention...
DAX Remains Positive Despite Coming Off Early Highs; Bayer Soars Nearly 10%
(RTTNews) - Despite coming off early highs, Germany's benchmark DAX is up firmly in positive territory on Monday, amid renewed hopes of a Fed interest rate in December, and signs of progress in Ukrain...
European Stocks Gain With Boost From Dovish Fed Comments, Bayer
European stocks gained as sentiment was lifted by dovish Federal Reserve comments and early talks about potential Nvidia Corp. chip sales to China. Bayer AG rallied after releasing promising study res...
Bayer stock jump 9% as stroke drug trial revives confidence in pipeline
Bayer shares surged on Monday after the company reported encouraging late-stage clinical trial results for its experimental cardiovascular drug asundexian, offering a rare boost for a pharmaceutical d...
Stocks to Watch Monday: Alibaba, Tesla, Alphabet, Bayer
Bayer’s stock is jumping on secondary stroke drug’s trial success
Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.
Bayer shares up more than 8% on revived fortunes for blood thinner
Shares in Bayer jumped more than 8% on Monday after initial clinical trial results turned around the fortunes of a key cardiovascular drug that suffered a major development setback two years ago.
Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment
The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during the study.
Bayer's Asundexian Meets Primary Goals In Phase III Study In Secondary Stroke Prevention
(RTTNews) - Bayer AG (BAYZF.PK) late Sunday announced positive topline results from Phase III OCEANIC-STROKE study with its investigational, once daily, oral FXIa inhibitor asundexian, in secondary st...
Bayer reports positive results for blood thinner after 2023 setback
German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
Bayer's Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study ...
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
EQS-Ad-hoc: Bayer Aktiengesellschaft / Key word(s): Study results Bayer Aktiengesellschaft: Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in S...
FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising
The Food and Drug Administration (FDA) on Wednesday granted accelerated approval to Bayer AG ‘s (OTC: BAYRY) Hyrnuo (sevabertinib) for adults with a specific type of advanced lung cancer . The approv...
FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising
The Food and Drug Administration (FDA) on Wednesday granted accelerated approval to Bayer AG‘s (OTC: BAYRY) Hyrnuo (sevabertinib) for adults with a specific type of advanced lung cancer.
Bayer wins FDA accelerated approval for Hyrnuo in lung cancer
EQS-News: TetraScience and Bayer Expand Partnership to Advance Scientific Data Management
EQS-News: TetraScience / Key word(s): Miscellaneous TetraScience and Bayer Expand Partnership to Advance Scientific Data Management 20.11.2025 / 12:05 CET/CEST The issuer is solely responsible for the...
Bayer Just Cracked the Lung Cancer Market--Here's Why Investors Are Paying Attention
Bayer Just Cracked the Lung Cancer Market--Here's Why Investors Are Paying Attention
US FDA approves Bayer's lung cancer drug
The U.S. Food and Drug Administration on Wednesday approved Bayer's drug for patients with a type of lung cancer.
Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target
Siemens AG (OTCPK: SIEGY) has warned that adverse currency movements will weigh on its results next year, even as the German manufacturer expects the global economic environment to remain stabilize ne...
Bayer Aktiengesellschaft (BAYRY) Q3 2025 Earnings Call Transcript
Bayer Aktiengesellschaft (OTCPK:BAYRY) Q3 2025 Earnings Call November 12, 2025 8:00 AM ESTCompany ParticipantsJost Reinhard - Senior VP & Head of...